Notch Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Notch Therapeutics's estimated annual revenue is currently $13.6M per year.
- Notch Therapeutics's estimated revenue per employee is $155,000
- Notch Therapeutics's total funding is $86M.
Employee Data
- Notch Therapeutics has 88 Employees.
- Notch Therapeutics grew their employee count by -20% last year.
Notch Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Stem Cell Biology and Developmental Immunology | Reveal Email/Phone |
2 | SVP, Technical Operations | Reveal Email/Phone |
3 | EVP, Finance and CFO | Reveal Email/Phone |
4 | Director Process Development | Reveal Email/Phone |
5 | Director, Protein & Cell Engineering | Reveal Email/Phone |
6 | Director, People and Culture | Reveal Email/Phone |
7 | Director Business Development | Reveal Email/Phone |
8 | Senior Director, Engineering | Reveal Email/Phone |
9 | Senior Director, Manufacturing Sciences | Reveal Email/Phone |
10 | Director, Project Management | Reveal Email/Phone |
Notch Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is Notch Therapeutics?
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
keywords:N/A
$86M
Total Funding
88
Number of Employees
$13.6M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Notch Therapeutics News
Halozyme Therapeutics (NASDAQ:HALO) Financial Contrast ... Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial...
VANCOUVER, BC , April 6, 2022 /PRNewswire/ -- Notch Therapeutics, Inc., ... induced pluripotent stem cell (iPSC)-derived cell therapies for...
Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he co...
Notch Therapeutics is commercializing technologies developed in the labs of Juan-Carlos Zúñiga-Pflücker, left, chair of Notch’s scientific advisory board, and Chief Scientific Officer Peter Zandstra. (University of Toronto and Notch Photos) New funding: Notch Therapeutics has raised a $85 milli ...
Notch Therapeutics, Inc., a Vancouver, BC-based biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, closed an U.S. $85m Series A financing. The round was led by an exclusively healthcare-focused investment fund, with participation ...
Other Companies in Toronto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.8M | 88 | 16% | N/A |
#2 | $56.3M | 88 | -12% | $33.7M |
#3 | $21.6M | 88 | 4% | $85.9M |
#4 | $12.8M | 88 | 11% | N/A |
#5 | $31.1M | 88 | 11% | N/A |